{"organizations": [], "uuid": "43cc477e25d417b7e92b2614bb471d30c89b0dd2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180131.html", "section_title": "Archive News &amp; Video for Wednesday, 31 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncology-venture-announces-positiv/brief-oncology-venture-announces-positive-interim-results-from-a-phase-1-2-study-idUSFWN1PQ0G3", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncology Venture Announces Positive Interim Results From A Phase 1/2 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T16:34:00.000+02:00", "replies_count": 0, "uuid": "43cc477e25d417b7e92b2614bb471d30c89b0dd2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncology-venture-announces-positiv/brief-oncology-venture-announces-positive-interim-results-from-a-phase-1-2-study-idUSFWN1PQ0G3", "ord_in_thread": 0, "title": "BRIEF-Oncology Venture Announces Positive Interim Results From A Phase 1/2 Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "sweden", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 31 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:\n* ANNOUNCES POSITIVE INTERIM RESULTS FROM A PHASE 1/2 STUDY WITH LIPLACIS AND ITS DRP IN HEAVILY PRETREATED METASTATIC BREAST CANCER PATIENTS\n* STUDY IS PROGRESSING ACCORDING TO PLAN, AND LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.\n* ‍LAST PATIENT IS EXPECTED TO BE INCLUDED BEFORE END OF Q1 2018.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-31T16:34:00.000+02:00", "crawled": "2018-02-01T15:48:40.006+02:00", "highlightTitle": ""}